Profile data is unavailable for this security.
About the company
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-216.81m
- Incorporated2016
- Employees111.00
- LocationCullinan Therapeutics IncOne Main Street, Suite 1350CAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 410-4650
- Fax+1 (302) 655-5049
- Websitehttps://cullinantherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sellas Life Sciences Group Inc | 0.00 | -25.94m | 611.31m | 15.00 | -- | 9.84 | -- | -- | -0.2869 | -0.2869 | 0.00 | 0.3648 | 0.00 | -- | -- | 0.00 | -66.47 | -125.08 | -84.33 | -231.32 | -- | -- | -- | -1,399.79 | -- | -- | 0.00 | -- | -- | -- | 17.30 | -- | -- | -- |
| enGene Holdings Inc | 0.00 | -117.30m | 655.11m | 45.00 | -- | 3.03 | -- | -- | -2.29 | -2.29 | 0.00 | 3.22 | 0.00 | -- | -- | 0.00 | -44.05 | -- | -48.27 | -- | -- | -- | -- | -- | -- | -- | 0.1221 | -- | -- | -- | -112.73 | -- | 50.55 | -- |
| Replimune Group Inc | 0.00 | -314.85m | 658.10m | 479.00 | -- | 3.01 | -- | -- | -3.44 | -3.44 | 0.00 | 2.64 | 0.00 | -- | -- | 0.00 | -67.19 | -33.04 | -75.03 | -35.07 | -- | -- | -- | -- | -- | -- | 0.2565 | -- | -- | -- | -14.60 | -- | 0.4456 | -- |
| LB Pharmaceuticals Inc | 0.00 | -18.80m | 667.66m | 16.00 | -- | 1.90 | -- | -- | -0.82 | -0.82 | 0.00 | 12.26 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -905.61 | -- | -- | -- |
| Cullinan Therapeutics Inc | 0.00 | -216.81m | 684.69m | 111.00 | -- | 1.52 | -- | -- | -3.68 | -3.68 | 0.00 | 7.64 | 0.00 | -- | -- | 0.00 | -38.12 | -16.54 | -40.13 | -17.34 | -- | -- | -- | -1,797.10 | -- | -- | 0.00 | -- | -- | -- | -9.28 | -- | -- | -- |
| YD Bio Ltd | -100.00bn | -100.00bn | 693.93m | 5.00 | -- | 136.38 | -- | -- | -- | -- | -- | 0.0722 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.36 | -- | 0.0124 | -- | 45.76 | -- | -10,509.73 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 0.00 | -71.11m | 701.26m | 45.00 | -- | 2.90 | -- | -- | -1.14 | -1.14 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -28.80 | -35.63 | -30.41 | -38.94 | -- | -- | -- | -314.68 | -- | -- | 0.00 | -- | 2,752.05 | -- | 90.01 | -- | -20.09 | -- |
| Annexon Inc | 0.00 | -208.88m | 706.83m | 99.00 | -- | 3.49 | -- | -- | -1.39 | -1.39 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -68.11 | -42.65 | -76.07 | -45.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.95 | -- | -43.78 | -- |
| Kura Oncology Inc | 104.03m | -216.88m | 723.12m | 192.00 | -- | 2.98 | -- | 6.95 | -2.48 | -2.48 | 1.19 | 2.79 | 0.1844 | -- | -- | 541,817.70 | -38.45 | -26.38 | -44.88 | -28.06 | -- | -- | -208.48 | -1,266.72 | -- | -- | 0.0384 | -- | -- | -- | -13.99 | -- | -- | -- |
| Gyre Therapeutics Inc | 107.27m | 6.65m | 728.94m | 574.00 | 124.24 | 7.15 | 51.69 | 6.80 | 0.0646 | 0.0646 | 1.09 | 1.12 | 0.7537 | 0.6368 | 4.73 | 186,872.80 | 8.30 | -53.99 | 12.90 | -82.36 | 95.48 | 89.58 | 11.01 | -88.61 | 5.64 | -- | 0.00 | -- | -6.78 | -- | 113.00 | -- | 117.68 | -- |
| Personalis Inc | 69.10m | -73.88m | 729.08m | 229.00 | -- | 4.25 | -- | 10.55 | -0.8761 | -0.8761 | 0.8189 | 1.93 | 0.2863 | 7.71 | 4.96 | 301,759.80 | -30.61 | -29.82 | -36.03 | -34.69 | 26.67 | 28.44 | -106.92 | -105.71 | 4.69 | -- | 0.0133 | -- | 15.15 | 5.35 | 24.94 | -- | -28.17 | -- |
| Jade Biosciences Inc | 0.00 | -65.26m | 741.19m | 4.00 | -- | 2.73 | -- | -- | -11.45 | -11.45 | 0.00 | 5.50 | 0.00 | -- | -- | 0.00 | -44.48 | -47.29 | -50.06 | -50.63 | -- | -- | -- | -- | -- | -320.04 | 0.00 | -- | -- | -- | 7.80 | -- | -- | -- |
| Arvinas Inc | 312.30m | -58.50m | 748.21m | 430.00 | -- | 1.46 | -- | 2.40 | -0.8048 | -0.8048 | 4.30 | 7.97 | 0.3105 | -- | 22.63 | 726,279.10 | -5.82 | -20.58 | -7.36 | -25.05 | -- | -- | -18.73 | -211.50 | -- | -- | 0.0007 | -- | 235.54 | 43.71 | 45.85 | -- | -22.02 | -- |
| Kalvista Pharmaceuticals Inc | 15.12m | -210.31m | 753.65m | 270.00 | -- | 44.33 | -- | 49.85 | -3.95 | -3.95 | 0.2838 | 0.3363 | 0.0604 | -- | 1.51 | 55,992.59 | -84.00 | -49.86 | -97.02 | -54.21 | 87.95 | -- | -1,391.14 | -- | 7.21 | -82.77 | 0.9412 | -- | -- | -- | -44.85 | -- | 33.39 | -- |
| Maravai Lifesciences Holdings Inc | 192.28m | -121.24m | 756.89m | 550.00 | -- | 3.08 | -- | 3.94 | -0.8442 | -0.8442 | 1.34 | 0.961 | 0.1808 | 3.18 | 7.48 | 337,338.60 | -20.14 | 8.27 | -27.68 | 10.45 | 20.86 | 72.61 | -111.42 | 25.48 | 4.56 | -7.37 | 0.4288 | 0.00 | -10.30 | 12.61 | -21.69 | -- | 12.69 | -- |
| MiMedx Group Inc | 393.44m | 40.83m | 758.28m | 837.00 | 18.75 | 3.17 | 13.67 | 1.93 | 0.273 | 0.273 | 2.63 | 1.61 | 1.40 | 2.79 | 5.95 | 470,062.10 | 14.51 | 2.94 | 17.63 | 3.89 | 81.99 | 83.00 | 10.38 | 2.07 | 3.95 | -- | 0.0708 | -- | 8.52 | 3.12 | -24.73 | -- | -5.37 | -- |
Data as of Feb 13 2026. Currency figures normalised to Cullinan Therapeutics Inc's reporting currency: US Dollar USD
55.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Lynx1 Capital Management LPas of 28 Oct 2025 | 8.96m | 15.17% |
| BVF Partners LPas of 30 Sep 2025 | 5.75m | 9.73% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.89m | 6.58% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.92m | 4.94% |
| Kynam Capital Management LPas of 30 Sep 2025 | 2.30m | 3.90% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 2.20m | 3.72% |
| Affinity Asset Advisors LLCas of 31 Dec 2025 | 1.93m | 3.27% |
| Citadel Advisors LLCas of 30 Sep 2025 | 1.84m | 3.12% |
| RTW Investments LPas of 30 Sep 2025 | 1.71m | 2.89% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.30m | 2.20% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
